Renal Cell Cancer Metastatic Clinical Trial
Official title:
Phase II Trial of Moderate Dose Bolus Interleukin-2 in Metastatic Kidney Cancer
The purpose of this study is to determine whether Interleukin-2 at the dose and schedule used in this study will help increase tumor shrinkage.
In this phase II study, the IL-2 schedule (daily IL-2 for 5 days (per week) every 3 weeks) will be tested in a cohort of kidney cancer patients to attempt to determine the response rate, median duration of response, and median survival. The dose intensity of this schedule would allow a patient treated on this regimen to achieve the target threshold (> 1440 million IU/m2/year). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
| Completed |
NCT04368546 -
Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)
|
||
| Recruiting |
NCT04903873 -
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06264479 -
Prospective Evaluation of AI R&D Tool for Patient Stratification: a Trial for Renal Immuno-oncology Model Experimental Evaluation 2
|
||
| Terminated |
NCT03876925 -
A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC
|
Phase 1/Phase 2 | |
| Completed |
NCT01658813 -
5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05326620 -
National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)
|
||
| Active, not recruiting |
NCT03095040 -
CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma
|
Phase 3 | |
| Completed |
NCT04749602 -
Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.
|
Phase 2 |